M&APfizer-Seagen: Acquisition in the worksPfizer strengthens its oncology portfolio by acquiring Seagen, the biotech specialist in antibody-drug conjugates technology. more ➔
financingIktos SA raises €15.5m in Series A finan... Paris-based AI-inspired drug discovery specialist Iktos SA has closed a €15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics. more ➔
partnershipCollaboration to fight cancerThe charity Cancer Research UK and UCB SA collaborate on the development of two potential cures for cancer. more ➔
financingNoema Pharma AG closes Series B financingNoema Pharma AG receives €104m in oversubscribed Series B financing round to advance its central nervous system pipeline. more ➔
IPOOculis lists at Nasdaq through SPAC mergerThe eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp. more ➔
financingMoney for AI-powered drug discoveryAntiverse Ltd.s AI identified eight antibodies with therapeutic potential for humans and raised €2.8m in funding for continued in-house development. more ➔
partnershipConfo Therapeutics and Lilly partner to ad...Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554. more ➔
fundraisingGerman HTGF IV fund closes at €493mThe fourth fund of High-Tech Gründerfonds has reached a final fund volume of €493.8m more ➔
financing5 Alarm Bio Ltd raises £500K in seed roun...British anti-aging therapeutics developer 5 Alarm Bio Ltd has raised £500K in a seed financing for testing its lead compound FAB001 for healing chronic wounds. more ➔
immunologyHigh blood pressure reprograms immune syst...Interferon-gamma overexpression leads to hypertension-induced damage to the blood-brain barrier by reprogrammed macrophages. more ➔